CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC CStone Pharmaceuticals has received new indication approval from the UK MHRA for sugemalimab, aimed at patients with Stage III non-small cell lung cancer, expanding its global reach.

CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC #United_Kingdom #N/A #NSCLC #CStone #Sugemalimab

CStone Pharmaceuticals Moves Forward with CS5001 Clinical Trials in Australia for DLBCL Treatment CStone Pharmaceuticals has submitted a clinical trial application in Australia to assess CS5001 for treating DLBCL, combining it with standard-of-care therapies. This marks a significant advancement in cancer treatment.

CStone Pharmaceuticals Moves Forward with CS5001 Clinical Trials in Australia for DLBCL Treatment #Suzhou #Australia #CS5001 #DLBCL #CStone

CStone Pharmaceuticals' Sugemalimab Study Breaks Ground in Gastric Cancer Treatment with New JAMA Publication CStone Pharmaceuticals has announced groundbreaking results from the GEMSTONE-303 study, showcasing sugemalimab's efficacy as a first-line treatment for gastric cancer, now published in JAMA.

CStone Pharmaceuticals' Sugemalimab Study Breaks Ground in Gastric Cancer Treatment with New JAMA Publication #China #Suzhou #CStone #Sugemalimab #JAMA

CStone Pharmaceuticals Celebrates New ESMO Guideline Inclusion for Sugemalimab Treatment in NSCLC CStone Pharmaceuticals announces its leading cancer therapy, Sugemalimab, is now part of ESMO's guidelines for NSCLC, marking a significant milestone.

CStone Pharmaceuticals Celebrates New ESMO Guideline Inclusion for Sugemalimab Treatment in NSCLC #China #Suzhou #NSCLC #CStone #Sugemalimab

CStone Pharmaceuticals Enters Strategic Partnership with SteinCares for Sugemalimab in Latin America CStone partners with SteinCares for the commercialization of Sugemalimab across 10 Latin American countries. This deal marks a significant milestone for both companies in expanding access to innovative cancer therapies.

CStone Pharmaceuticals Enters Strategic Partnership with SteinCares for Sugemalimab in Latin America #China #Suzhou #SteinCares #CStone #Sugemalimab

CStone Pharmaceuticals Submits Clinical Trial Application for Innovative Cancer Treatment in Australia CStone Pharmaceuticals has submitted a clinical trial application in Australia for CS2009, a groundbreaking trispecific antibody aimed at treating various solid tumors.

CStone Pharmaceuticals Submits Clinical Trial Application for Innovative Cancer Treatment in Australia #Shanghai #Cancer_Treatment #Australia #CStone #CS2009